Explant Modeling of the Immune Environment of Head and Neck Cancer
Open Access
- 17 June 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
Abstract
Patients exhibit distinct responses to immunotherapies that are thought to be linked to their tumor immune environment. However, wide variations in outcomes are also observed in patients with matched baseline tumor environments, indicating that the biological response to treatment is not currently predictable using a snapshot analysis. To investigate the relationship between the immune environment of tumors and the biological response to immunotherapies, we characterized four murine head and neck squamous cell carcinoma (HNSCC) models on two genetic backgrounds. Using tumor explants from those models, we identified correlations between the composition of infiltrating immune cells and baseline cytokine profiles prior to treatment. Following treatment with PD-1 blockade, CTLA-4 blockade, or OX40 stimulation, we observed inter-individual variability in the response to therapy between genetically identical animals bearing the same tumor. These distinct biological responses to treatment were not linked to the initial tumor immune environment, meaning that outcome would not be predictable from a baseline analysis of the tumor infiltrates. We similarly performed the explant assay on patient HNSCC tumors and found significant variability between the baseline environment of the tumors and their response to therapy. We propose that tumor explants provide a rapid biological assay to assess response to candidate immunotherapies that may allow matching therapies to individual patient tumors. Further development of explant approaches may allow screening and monitoring of treatment responses in HNSCC.Funding Information
- National Institutes of Health (R01CA182311, R01CA244142, R01CA208644)
- Israel Cancer Association
- Israel Science Foundation
This publication has 58 references indexed in Scilit:
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)Journal for ImmunoTherapy of Cancer, 2019
- Novel prognostic clinical factors and biomarkers for outcome prediction in head and neck cancer: a systematic reviewThe Lancet Oncology, 2019
- Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic CancerJAMA Surgery, 2018
- Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumorsNature Communications, 2018
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltratesNature, 2018
- Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunityScientific Reports, 2018
- The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysisOncoImmunology, 2017
- Multiparametric immune profiling in HPV– oral squamous cell cancerJCI Insight, 2017
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironmentJournal for ImmunoTherapy of Cancer, 2014
- Association between severe treatment‐related lymphopenia and progression‐free survival in patients with newly diagnosed squamous cell head and neck cancerHead & Neck, 2013